ClinicalTrials.gg
CompletedNCT04548219Updated Jan 25, 2024Results posted

A Study to Compare Two Different Formulations of Mirikizumab in Healthy Participants

A Phase 1 interventional study of Mirikizumab in Healthy, sponsored by Eli Lilly and Company. Completed at 1 site in United States. Open to participants aged 18 Years to 75 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-01-25.

Sponsored by Eli Lilly and Company · Phase 1, Interventional, and Basic science

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
60
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Study summary

The purpose of this study is to compare two different formulations of mirikizumab in healthy participants. This study will compare how much of each formulation gets into the blood stream and how long it takes the body to remove it. Information about any side effects that may occur will also be collected. Participants will remain in the study for about 12 weeks, after receiving study drug.

02

Conditions studied

  • Healthy
03

In context

Lead sponsor

Eli Lilly and Company is the lead sponsor of 2,108 studies on the registry; 153 are open to participants now.

Of its 537 completed or terminated interventional studies of FDA-regulated products, 358 (67%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Are overtly healthy males or females, as determined through medical history and physical examination

Exclusion criteria

Exclusion Criteria:

  • Must not have an average weekly alcohol intake that exceeds 21 units/week (males) and 14 units/week (females)
  • Must not show evidence of active or latent tuberculosis (TB)
  • Must not have received (s) (including attenuated live vaccines and those administered intranasally) within 8 weeks of screening, or intend to during the study
  • Must not have been treated with within 1 month of screening, or intend to during the study
  • Must not be
  • Must not have received treatment with biologic agents (e.g. monoclonal antibodies, including marketed drugs) within 3 months or 5 half-lives (whichever is longer) prior to Day 1
  • Must not have multiple or severe drug allergies, or intolerance to topical corticosteroids, or severe post treatment reactions
  • Must not have had lymphoma, leukemia, or any within the past 5 years except for basal cell or squamous epithelial carcinomas of the skin that have been resected with no evidence of disease for 3 years
  • Must not have had breast cancer within the past 10 years
  • Must not have significant allergies to humanized monoclonal antibodies
  • Must not have clinically significant multiple or severe drug allergies, or intolerance to topical corticosteroids, or severe post treatment hypersensitivity reactions
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

05

Study design

Phase
Phase 1
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
60 participants (actual)

Study arms

  • Experimental
    Mirikizumab (Reference)

    200 milligram (mg) of mirikizumab as reference formulation (100 mg/mL), 2 × 1-mL pre-filled syringe administered as a subcutaneous (SC) injection into the arm/thigh/abdomen on day 1.

    Drug: Mirikizumab

  • Experimental
    Mirikizumab (Test)

    200 mg of mirikizumab as test formulation (100 mg/mL), 2 × 1-mL pre-filled syringe administered as a SC injection into the arm/thigh/abdomen on day 1.

    Drug: Mirikizumab

Interventions

  • Reference and test formulations of mirikizumab administered as a SC injection.

    Also known as: LY3074828

06

What researchers measure

Primary outcomes

  1. Pharmacokinetics (PK): Maximum Concentration (Cmax) of Mirikizumab

    PK: Cmax of mirikizumab was evaluated.

    Time frame: Predose on Day 1, Day 3, Day 5, Day 8, Day 11, Day 15, Day 22, Day 29, Day 43, Day 57, Day 71 and Day 85 postdose

  2. PK: Area Under the Concentration Versus Time Curve From Time Zero to Infinity (AUC[0-inf]) of Mirikizumab

    PK: AUC(0-inf) of mirikizumab was evaluated.

    Time frame: Predose on Day 1, Day 3, Day 5, Day 8, Day 11, Day 15, Day 22, Day 29, Day 43, Day 57, Day 71 and Day 85 postdose

  3. PK: Area Under the Concentration Versus Time Curve From Time Zero to t, Where t is the Last Timepoint With a Measurable Concentration (AUC[0-tlast]) of Mirikizumab

    PK: (AUC\[0-tlast\]) of mirikizumab was evaluated.

    Time frame: Predose on Day 1, Day 3, Day 5, Day 8, Day 11, Day 15, Day 22, Day 29, Day 43, Day 57, Day 71 and Day 85 postdose

07

Results

Posted Jan 25, 2024

Participant flow

Participant flow — Overall Study
Milestone200 Milligram (mg) Mirikizumab (Reference): Arm200 mg Mirikizumab (Reference): Thigh200 mg Mirikizumab (Reference): Abdomen200 mg Mirikizumab (Test): Arm200 mg Mirikizumab (Test): Thigh200 mg Mirikizumab (Test): Abdomen
Started101010101010
Received at least 1 dose of study drug101010101010
Completed101010101010
Not completed000000

Outcome measures

PrimaryPharmacokinetics (PK): Maximum Concentration (Cmax) of Mirikizumab

PK: Cmax of mirikizumab was evaluated.

Time frame:
Predose on Day 1, Day 3, Day 5, Day 8, Day 11, Day 15, Day 22, Day 29, Day 43, Day 57, Day 71 and Day 85 postdose
Reported as:
Geometric mean · micrograms per milliliter (ug/mL)
Pharmacokinetics (PK): Maximum Concentration (Cmax) of Mirikizumab
micrograms per milliliter (ug/mL)200 mg Mirikizumab (Reference)200 mg Mirikizumab (Test)
Pharmacokinetics (PK): Maximum Concentration (Cmax) of Mirikizumab12.7 ± 4811.6 ± 45
Statistical analysis
  • 200 mg Mirikizumab (Reference) vs 200 mg Mirikizumab (Test) · Ratio of geometric least squares mean: 0.907 · 90% CI 0.775 to 1.06
PrimaryPK: Area Under the Concentration Versus Time Curve From Time Zero to Infinity (AUC[0-inf]) of Mirikizumab

PK: AUC(0-inf) of mirikizumab was evaluated.

Time frame:
Predose on Day 1, Day 3, Day 5, Day 8, Day 11, Day 15, Day 22, Day 29, Day 43, Day 57, Day 71 and Day 85 postdose
Reported as:
Geometric mean · ug*day/mL
PK: Area Under the Concentration Versus Time Curve From Time Zero to Infinity (AUC[0-inf]) of Mirikizumab
ug*day/mL200 mg Mirikizumab (Reference)200 mg Mirikizumab (Test)
PK: Area Under the Concentration Versus Time Curve From Time Zero to Infinity (AUC[0-inf]) of Mirikizumab229 ± 56209 ± 45
Statistical analysis
  • 200 mg Mirikizumab (Reference) vs 200 mg Mirikizumab (Test) · Ratio of geometric least squares mean: 0.915 · 90% CI 0.761 to 1.10
PrimaryPK: Area Under the Concentration Versus Time Curve From Time Zero to t, Where t is the Last Timepoint With a Measurable Concentration (AUC[0-tlast]) of Mirikizumab

PK: (AUC\[0-tlast\]) of mirikizumab was evaluated.

Time frame:
Predose on Day 1, Day 3, Day 5, Day 8, Day 11, Day 15, Day 22, Day 29, Day 43, Day 57, Day 71 and Day 85 postdose
Reported as:
Geometric mean · ug*day/mL
PK: Area Under the Concentration Versus Time Curve From Time Zero to t, Where t is the Last Timepoint With a Measurable Concentration (AUC[0-tlast]) of Mirikizumab
ug*day/mL200 mg Mirikizumab (Reference)200 mg Mirikizumab (Test)
PK: Area Under the Concentration Versus Time Curve From Time Zero to t, Where t is the Last Timepoint With a Measurable Concentration (AUC[0-tlast]) of Mirikizumab225 ± 56206 ± 46
Statistical analysis
  • 200 mg Mirikizumab (Reference) vs 200 mg Mirikizumab (Test) · Ratio of geometric least squares mean: 0.915 · 90% CI 0.760 to 1.10

Adverse events

Collected over Up To 85 Days. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
200 mg Mirikizumab (Reference): Arm0/10 (0%)0/10 (0%)0/10 (0%)
200 mg Mirikizumab (Reference): Thigh0/10 (0%)0/10 (0%)2/10 (20%)
200 mg Mirikizumab (Reference): Abdomen0/10 (0%)0/10 (0%)1/10 (10%)
200 mg Mirikizumab (Test): Arm0/10 (0%)0/10 (0%)0/10 (0%)
200 mg Mirikizumab (Test): Thigh0/10 (0%)0/10 (0%)0/10 (0%)
200 mg Mirikizumab (Test): Abdomen0/10 (0%)0/10 (0%)3/10 (30%)
Most frequent other events
Most frequent other events
Event200 mg Mirikizumab (Reference): Arm200 mg Mirikizumab (Reference): Thigh200 mg Mirikizumab (Reference): Abdomen200 mg Mirikizumab (Test): Arm200 mg Mirikizumab (Test): Thigh200 mg Mirikizumab (Test): Abdomen
NauseaGastrointestinal disorders0/102/100/100/100/102/10
HeadacheNervous system disorders0/101/100/100/100/102/10
VomitingGastrointestinal disorders0/101/100/100/100/100/10
NasopharyngitisInfections and infestations0/100/100/100/100/101/10
Foot fractureInjury, poisoning and procedural complications0/100/101/100/100/100/10
AgeusiaNervous system disorders0/100/100/100/100/101/10
AnosmiaNervous system disorders0/100/100/100/100/101/10

Baseline characteristics

All participants who received at least 1 dose of study drug.

Age, Categorical
Age, Categorical(Participants)200 mg Mirikizumab (Reference)200 mg Mirikizumab (Test)Total
<=18 years000
Between 18 and 65 years262753
>=65 years437
Sex: Female, Male
Sex: Female, Male(Participants)200 mg Mirikizumab (Reference)200 mg Mirikizumab (Test)Total
Female192241
Male11819
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)200 mg Mirikizumab (Reference)200 mg Mirikizumab (Test)Total
Hispanic or Latino011
Not Hispanic or Latino302959
Unknown or Not Reported000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)200 mg Mirikizumab (Reference)200 mg Mirikizumab (Test)Total
American Indian or Alaska Native011
Asian000
Native Hawaiian or Other Pacific Islander000
Black or African American101
White292958
More than one race000
Unknown or Not Reported000
Region of Enrollment
Region of Enrollment(Participants)200 mg Mirikizumab (Reference)200 mg Mirikizumab (Test)Total
United States303060
08

Study locations

1 site
  • QPS
    Springfield, Missouri 65802, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Sep 2020 to primary completion in Jan 2021, 4 months.

Results were first posted in Jan 2024, 3 years after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 10, 2020
First posted
Sep 14, 2020
StartActual
Sep 11, 2020
Primary completionActual
Jan 11, 2021
CompletionActual
Jan 11, 2021
Results first posted
Jan 25, 2024
Last update
Jan 25, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 25, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04548219
Responsible party
Sponsor
First posted
Sep 14, 2020
Start date
Sep 11, 2020
Primary completion
Jan 11, 2021
Completion
Jan 11, 2021
Results posted
Jan 25, 2024
Last update
Jan 25, 2024

Study contacts

Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)
study director · Eli Lilly and Company

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Mirikizumab

Start the discussion